New microbiome and phenotype data from observational study will enlarge unique Ardigen’s database

Topic:

After two succeeded registrations of clinical studies at ClinicalTrial.gov, Ardigen finalized this process with next observational study: Microbiome Polish Map, NCT04169867. Ardigen, in cooperation with The Institute of Bioorganic Chemistry, Polish Academy of Sciences in Poznan, is building a unique set of scientific processed information describing the variability of the polish population microbiome.

 

A reliable dataset, which consists of 1000 healthy volunteers and 160 patients with melanoma treated with routine immunotherapy (anti-PD1, anti-PDL1 and/or anti CTLA4 antibodies), will characterize the gut microbiome diversity in the polish population. The collection of stool samples will be performed for each donor with information about eating habits and health survey. Samples will be sequenced by next-generation sequencing platform (Shotgun Metagenomics Sequencing).

 

The project is funded by Małopolskie Centre of Entrepreneurship (POIR.04.01.02-00-0025/17).

 

ClinicalTrials.gov is a resource which provides the public with easy access to information about clinical studies on a wide range of diseases and conditions conducted on human volunteers. This database is maintained by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in USA.

 

 

Read more at:

https://clinicaltrials.gov/ct2/show/NCT04169867

You might be also interested in:

Where AI Meets Wet-Lab: A Smarter Path to Biologics Discovery Success
Real-time analytics for Clinical Trials
Data Lakehouses: A Strategic Imperative for the Future of Clinical Studies?
Latest progress and tools for de novo generation of peptides

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!